📰 Multiple System Atrophy News
Page 22 - Multiple System Atrophy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple System Atrophy. Real-time updates on events, politics, business and more.
July 13, 2022
Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200
July 13, 2022
Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an...
July 13, 2022
Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an...
July 11, 2022
Using UT Southwestern's Cryo-Electron Microscopy Facility, researchers for the first time have captured images of an autoantibody bound to a nerve cell surface receptor, revealing the physical mechanism behind a neurological autoimmune disease.
July 7, 2022
MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"),...
July 6, 2022
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
July 6, 2022
MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (Alterity or the Company),...
June 23, 2022
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
June 16, 2022
Washington, DC (PRWEB) June 16, 2022 -- MCI USA’s Association Solutions division is pleased to announce that Joe Lindahl, CAE, Senior Associate, MCI USA, is
June 13, 2022
Phase 1/1b 101 study terminated early; demonstrated favorable safety, tolerability, and pharmacokinetic profile in single doses up to 325 mg and...